Lakefront Biotherapeutics NV current report, Q2 FY2024

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (a foreign private issuer), not Lakefront Biotherapeutics NV, for the month of June 2024. The filing, dated June 17, 2024, incorporates by reference a press release issued on June 14, 2024 (Exhibit 99.1). The registrant is headquartered in Mechelen, Belgium, and files annual reports on Form 20-F.

Financial Metrics

The provided filing text serves as a cover document incorporating a press release and does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity within this text.

Material Changes

The filing text does not describe material changes in financial performance or operations. It solely references the issuance of a press release on June 14, 2024, the content of which is not included in the provided text.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It notes that the press release (Exhibit 99.1) contains a quote from Dr. Jeevan Shetty, but the text of the quote is not included in the source material.

Key Facts for Investor Verification

  • Entity Discrepancy: The filing is for Galapagos NV, despite the request metadata referencing Lakefront Biotherapeutics NV.
  • Missing Content: The actual content of the June 14, 2024 press release (Exhibit 99.1) is not present in the provided text; investors must access the full filing to review the announcement.
  • No Financials: No financial metrics are reported in this specific document text.
  • Regulatory Status: The company confirms it files annual reports on Form 20-F.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.